Changes in glycemic control and skeletal muscle mass indices after dapagliflozin treatment in individuals with type 1 diabetes mellitus

Changes in glycemic control and skeletal muscle mass indices after dapagliflozin treatment in individuals with type 1 diabetes mellitus

Abstract Aims/Introduction Dapagliflozin is used for individuals with type 1 diabetes, although the effect of this medication on skeletal muscle mass is not well established. In addition, there are few studies examining the effects of good glycemic control on skeletal muscle mass in type 1 diabetes...

Full description

Bibliographic Details
Main Authors: Yuta Yoshimura, Yoshitaka Hashimoto, Hiroshi Okada, Maya Takegami, Hanako Nakajima, Tomoki Miyoshi, Takashi Yoshimura, Masahiro Yamazaki, Masahide Hamaguchi, Michiaki Fukui
Format: Article
Language:English
Published: Wiley 2023-10-01
Series:Journal of Diabetes Investigation
Subjects:
Sarcopenia
Skeletal muscle mass
Sodium–glucose cotransporter 2 inhibitor
Online Access:https://doi.org/10.1111/jdi.14054

Internet

https://doi.org/10.1111/jdi.14054

Similar Items